Myelofibrosis – Current Treatment – Detailed, Expanded Analysis : Physician Insights (US)
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Incyte’s ruxolitinib (Jakafi, approved November 2011) and Bristol Myers Squibb’s (BMS’s) fedratinib (Inrebic, approved August 2019) are the only FDA-approved drugs to treat MF. Although Jakafi is an important therapeutic option, discontinuation and/or loss of response may occur, and it does not address all MF symptoms. Therefore, significant market opportunity remains for additional safe and tolerable treatments that can manage the full spectrum of MF symptoms, as well as for treatments for patients with baseline thrombocytopenia and anemia. This report explores the current prescribing practices for MF, the various factors driving treatment decisions, and the changes in prescribing that are expected to occur in the coming year.
QUESTIONS ANSWERED
- Which symptoms do surveyed hematologists say are the most common among their MF patients? How do hematologists approach the management of MF patients? What factors drive physicians’ prescribing?
- What percentage of MF patients progress from one line of therapy to another based on severity? What is the treatment duration before progressing?
- Which drugs are the patient-share leaders in MF? How is Jakafi positioned in surveyed physicians’ treatment algorithms? How has the launch of Inrebic affected the management of MF?
- What are prescribers’ estimates regarding patients’ compliance with current therapies?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
GEOGRAPHY: United States
PRIMARY RESEARCH: Survey of 101 U.S. hematologists
KEY DRUGS COVERED: Ruxolitinib (Incyte’s Jakafi); fedratinib (BMS’s Inrebic); hydroxyurea; interferons
KEY INSIGHTS PROVIDED:
- Factors influencing disease management and treatment decisions.
- Drivers and constraints of treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Rationale for changes in treatment approach.
- Physician insight on persistency and compliance.
- Physician-reported recent/anticipated changes in brand usage or treatment approach.
Table of contents
- Myelofibrosis - Current Treatment - Detailed, Expanded Analysis : Physician Insights (US)
- Current Treatment Physician Insights Myelofibrosis US April 2021
Kanika Ujla, M.S., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. She conducts primary and secondary research in a range of antibacterial and antiviral indications, as well as numerous niche and rare diseases. She has experience in R&D, consulting, and business research with healthcare and life science companies. She obtained her master’s degree in biotechnology from the University of Jammu and her bachelor’s degree in biotechnology from Chaudhary Charan Singh University.